Rajavelu Esther sold Spero Therapeutics ($SPRO) shares on the open market four times over the past year, totaling about $344,000. Her most recent sale occurred on February 6, 2026. These sales rank her 7,292nd among 11,678 insiders by total value sold, well below the average of $8.6 million across roughly 6.4 transactions per insider. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 6, 2026 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | See Remarks | S | Common Stock | 50816 | $2.36 | 1,012,091.0000 | 56,339,295 | 4.78% | 0.09% |
| Feb. 6, 2026 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | See Remarks | S | Common Stock | 37101 | $2.36 | 1,062,907.0000 | 56,339,295 | 3.37% | 0.07% |
| Feb. 2, 2026 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | See Remarks | A | Common Stock | 249000 | $0.00 | 1,118,450.0000 | 56,339,295 | 28.64% | 0.44% |
| Feb. 2, 2026 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | See Remarks | A | Stock Option (Right to Buy) | 498000 | $0.00 | 498,000.0000 | 56,339,295 | 9999.99% | 0.88% |
| Feb. 2, 2026 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | See Remarks | S | Common Stock | 18442 | $2.20 | 1,100,008.0000 | 56,339,295 | 1.65% | 0.03% |
| Nov. 7, 2025 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | See Remarks | S | Common Stock | 40270 | $2.37 | 869,450.0000 | 56,339,295 | 4.43% | 0.07% |
| May 2, 2025 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | See Remarks | A | Common Stock | 185000 | $0.00 | 909,720.0000 | 55,900,641 | 25.53% | 0.33% |
| Feb. 3, 2025 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | CFO & CBO | A | Common Stock | 100000 | $0.00 | 745,409.0000 | 0 | 15.49% | 0.00% |
| Feb. 5, 2025 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | CFO & CBO | S | Common Stock | 20689 | $0.78 | 724,720.0000 | 0 | 2.78% | 0.00% |
| Feb. 3, 2025 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | CFO & CBO | A | Common Stock | 266139 | $0.00 | 645,409.0000 | 0 | 70.17% | 0.00% |
| Nov. 7, 2024 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | CFO & CBO | S | Common Stock | 23351 | $1.31 | 396,515.0000 | 0 | 5.56% | 0.00% |
| Nov. 8, 2024 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | CFO & CBO | S | Common Stock | 17245 | $1.30 | 379,270.0000 | 0 | 4.35% | 0.00% |
| Feb. 1, 2024 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | See Remarks | A | Common Stock | 119866 | $0.00 | 419,866.0000 | 0 | 39.96% | 0.00% |
| Nov. 13, 2023 | Spero Therapeutics, Inc. | $SPRO | Rajavelu Esther | See Remarks | A | Common Stock | 300000 | $0.00 | 300,000.0000 | 0 | 9999.99% | 0.00% |